VSBC — Vitaspring Biomedical Co. Income Statement
0.000.00%
HealthcareHighly SpeculativeSmall Cap
- $206.52m
- $206.50m
- $5.61m
Annual income statement for Vitaspring Biomedical Co., fiscal year end - January 31st, USD millions except per share, conversion factor applied.
2018 January 31st | 2019 January 31st | 2020 January 31st | 2021 January 31st | 2022 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.016 | 0.017 | 0.015 | 0.248 | 5.61 |
Cost of Revenue | |||||
Gross Profit | 0.011 | 0.014 | 0.002 | 0.112 | 2.07 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.023 | 0.04 | 0.017 | 0.674 | 4.13 |
Operating Profit | -0.006 | -0.022 | -0.002 | -0.425 | 1.48 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.006 | -0.022 | 0.007 | -0.425 | 1.48 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.006 | -0.022 | 0.007 | -0.425 | 1.26 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.006 | -0.022 | 0.007 | -0.425 | 1.26 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.006 | -0.022 | 0.007 | -0.425 | 1.26 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0 | -0 | -0 | -0.005 | 0.006 |
Dividends per Share |